Fulgent Genetics Inc. reported its first-quarter 2025 financial results, showcasing a core revenue growth of 16% year-over-year, amounting to $73.5 million. The company recorded a non-GAAP income of $1.2 million, translating to $0.04 per share. However, the GAAP results showed a loss of $11.5 million, reflecting a challenging period for the company. Fulgent maintained its full-year 2025 core revenue guidance at $310 million. The company ended the quarter with $814.6 million in cash, cash equivalents, restricted cash, and investments in marketable securities, equating to a cash per share value of $26.60. Fulgent remains optimistic about its growth prospects, bolstered by its Laboratory Services business and ongoing progress in its Therapeutic Development pipeline.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.